Last reviewed · How we verify
Cisplatin Chemotherapy
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death.
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death. Used for Metastatic testicular cancer, Metastatic ovarian cancer, Advanced bladder cancer.
At a glance
| Generic name | Cisplatin Chemotherapy |
|---|---|
| Also known as | radiotherapy, Lapatinib oral tablets |
| Sponsor | Cedars-Sinai Medical Center |
| Drug class | Platinum-based alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, disrupting DNA replication and transcription. This DNA damage triggers apoptosis in rapidly dividing cancer cells. It is a non-cell-cycle-phase-specific agent effective against a broad range of malignancies.
Approved indications
- Metastatic testicular cancer
- Metastatic ovarian cancer
- Advanced bladder cancer
- Head and neck cancer
- Non-small cell lung cancer
- Small cell lung cancer
Common side effects
- Nephrotoxicity
- Ototoxicity
- Nausea and vomiting
- Myelosuppression (thrombocytopenia)
- Myelosuppression (leukopenia)
- Peripheral neuropathy
- Anemia
- Electrolyte abnormalities (hypomagnesemia)
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin Chemotherapy CI brief — competitive landscape report
- Cisplatin Chemotherapy updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI